Baxdrostat

[anonymous]

So, when is this guaranteed failure of a drug going to launch?

 

[anonymous]

Mid 2026, can't be much worse the Airsupra at least

 

[anonymous]

Mid 2026, can't be much worse the Airsupra at least

Yet they are hiring reps now who will be promoting Farxiga (with an expiring patent looming, and an “authorized generic” already on the market). What’s the likelihood these new hires will actually still be around when Baxdrostat launches?

 

[anonymous]

Yet they are hiring reps now who will be promoting Farxiga (with an expiring patent looming, and an “authorized generic” already on the market). What’s the likelihood these new hires will actually still be around when Baxdrostat launches?

Nobody is getting hired for baxdrostat. Restructure right sized the salesforce for future farxiga cliff, baxdro launch and continued Lokelma promotion.

 

[anonymous]

Bax looks like a solid addition. Let's see if the tried and true pricing structure (greed) allows for very little coverage at launch. After all, that is the AZ way. If they do this right, Bax could be a huge win. Haven't had a new BP med in the mix in quite a long time, especially for refractory hypertension. Please do not price it like the PCSK9's for hypercholesterolemia or Brilinta as an anti-platelet. They never got the share they should have & neither will Bax if you ask for a premium price. Learn from the past...please!

 

[anonymous]

Yet they are hiring reps now who will be promoting Farxiga (with an expiring patent looming, and an “authorized generic” already on the market). What’s the likelihood these new hires will actually still be around when Baxdrostat launches?

If everything remains on track for a Mid 2026 launch things could be okay for the current sales force. The cost to cut then rehire doesn't make sense the closer to the end of the year we get. If needed they can have the reps do a disease state awareness campaign for a quarter or so. Now of course this is pharma and that can all be blown up

 

[anonymous]

If everything remains on track for a Mid 2026 launch things could be okay for the current sales force. The cost to cut then rehire doesn't make sense the closer to the end of the year we get. If needed they can have the reps do a disease state awareness campaign for a quarter or so. Now of course this is pharma and that can all be blown up

With present CVRM LT Baxdrostat won't survive!!! Something needs to change

 

[anonymous]

If everything remains on track for a Mid 2026 launch things could be okay for the current sales force. The cost to cut then rehire doesn't make sense the closer to the end of the year we get. If needed they can have the reps do a disease state awareness campaign for a quarter or so. Now of course this is pharma and that can all be blown up

They don't need reps to do disease state awareness ahead of time. Physicians are already fully aware of what is going on with hypertension and furthermore, they can do online campaigns, e-mails and CME for the providers until the drug is launched. Then disease state awareness will be done simultaneously.